Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
14 oct. 2020 07h00 HE
|
Novan, Inc.
- First demonstration of antiviral effect of nitric oxide-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results...
Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors
24 sept. 2020 07h05 HE
|
Novan, Inc.
- John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer - James L. Bierman, seasoned industry...
Novan Provides Pipeline and Priority Development Programs Update
14 sept. 2020 09h05 HE
|
Novan, Inc.
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 - - In vitro assessments of ability of...
Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
09 sept. 2020 08h05 HE
|
Novan, Inc.
- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT - MORRISVILLE, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or...
Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
03 sept. 2020 09h05 HE
|
Novan, Inc.
- Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved...
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
31 août 2020 08h05 HE
|
Novan, Inc.
- Clinical sites actively enrolling patients - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - ...
Novan President and CEO, Paula Brown Stafford Named Chairman of the Board
28 juil. 2020 08h05 HE
|
Novan, Inc.
Expanded role of Ms. Stafford as Chairman reflects the Board’s confidence in her leadership of the Company and strategic direction Renowned pharmaceutical executive Robert Ingram retiring as Executive...
Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders
23 juil. 2020 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annual...
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
25 juin 2020 08h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be...
Novan to Present at Virtual Life Sciences Investor Forum on June 25
24 juin 2020 08h15 HE
|
Novan, Inc.
MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive...